来自MSN5 个月
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial
Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for patients with ...
来自MSN5 天
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Shares of biotechnology company Rigel Pharmaceuticals, Inc. RIGL have surged 41.4% in the past year against the industry’s ...